|
|
|
|
|
|
|
|
|
|
Join Cell & Gene Live for "Scaling Next-Gen MSC Therapies Without Scaling Risk." Chief Editor Erin Harris hosts CEOs from Kiji Therapeutics, Mesoblast, and MEDIPOST to explore scaling cell production without losing therapeutic efficacy. Learn practical strategies for minimizing donor variability, preserving potency, and building commercially viable platforms. Don't risk clinical success—register for free today to secure your spot!
|
|
|
|
|
|
|
|
By Mark F. Witcher, Ph.D.
|
Since every sponsor–CDMO relationship can have widely different scopes, requirements, and procedures, this article focuses on the basic principles for analyzing and managing the risks of not achieving the relationship’s objectives.
|
|
|
|
|
|
|
|
|
|
Strengthening Lentiviral Vector Production With Platform Processes
|
|
Article | By Kim Allen, Joanna Manoranjan, and Kerry Adamik, Miltenyi Bioindustry
|
A robust platform process can help ensure therapeutic efficacy and supply chain security for LVV-based products, as well as support aggressive development and commercialization timelines.
|
|
|
|
|
|
From Plasmids To Cell-Free DNA For Advanced Gene Therapies
|
|
Application Note | By Elena Stoyanova, Ph.D., and Chesney Michels, Ph.D., Touchlight
|
Switching from bacterial plasmids to cell-free circular ssDNA boosts gene-editing safety and precision, reduces toxicity, enables up to 75% knock-in efficiency, and improves primary cell viability.
|
|
|
|
|
|
The Crucial Role Of Apheresis In Cellular Therapies
|
|
Webinar | Comprehensive Cell Solutions, A Business Unit of NYBC Enterprises
|
Rigorous adherence to collection protocols directly impacts patient outcomes. Listen as industry experts discuss best practices for maintaining strict quality standards during apheresis.
|
|
|
|
|
|
|
|
Streamline AAV-Based Gene Therapies With Off-The-Shelf Plasmids
|
|
White Paper | By George Buchman and Bhargavi Kondragunta, Catalent
|
Standardized, well-characterized plasmids and streamlined platform processes can significantly accelerate viral vector development, improve consistency, and support scalable, high-quality gene therapy manufacturing.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
|
